These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33846172)

  • 1. Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19.
    Aldea M; Michot JM; Danlos FX; Ribas A; Soria JC
    Cancer Discov; 2021 Jun; 11(6):1336-1344. PubMed ID: 33846172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing anticancer drugs for the management of COVID-19.
    El Bairi K; Trapani D; Petrillo A; Le Page C; Zbakh H; Daniele B; Belbaraka R; Curigliano G; Afqir S
    Eur J Cancer; 2020 Dec; 141():40-61. PubMed ID: 33125946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
    Dzobo K; Chiririwa H; Dandara C; Dzobo W
    OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of repurposed antiviral drugs: Lessons from COVID-19.
    Martinez MA
    Drug Discov Today; 2022 Jul; 27(7):1954-1960. PubMed ID: 35192924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
    Shawki MA; Elsayed NS; Mantawy EM; Said RS
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing of Anti-Cancer Drugs Against Moderate and Severe COVID Infection: A Network-Based Systems Biological Approach.
    Alzahrani KJ
    Niger J Clin Pract; 2024 Aug; 27(8):950-957. PubMed ID: 39212430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Existing Drugs Considered as Promising in COVID-19 Therapy.
    Janik E; Niemcewicz M; Podogrocki M; Saluk-Bijak J; Bijak M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.
    Amere Subbarao S
    Inflammopharmacology; 2021 Apr; 29(2):343-366. PubMed ID: 33723711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
    Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
    Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
    [No Abstract]   [Full Text] [Related]  

  • 13. Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system.
    Punekar M; Kshirsagar M; Tellapragada C; Patil K
    Microb Pathog; 2022 Jul; 168():105608. PubMed ID: 35654381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
    Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
    Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.
    Talukdar J; Bhadra B; Dattaroy T; Nagle V; Dasgupta S
    Biomed Pharmacother; 2020 Dec; 132():110886. PubMed ID: 33113418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing Antimalarials to Tackle the COVID-19 Pandemic.
    Krishna S; Augustin Y; Wang J; Xu C; Staines HM; Platteeuw H; Kamarulzaman A; Sall A; Kremsner P
    Trends Parasitol; 2021 Jan; 37(1):8-11. PubMed ID: 33153922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.